arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

LIFECORE BIOMEDICAL, INC. \DE\

LFCR
$5.02 ▲ +0.18 (+3.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

LIFECORE BIOMEDICAL, INC. \DE\ faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC None
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -5.23
info Valuation on last close. End-of-day price, Aug 7, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$31.11M
↑ +25.9%
Net Income Profit after all expenses
$-9.99M
↑ +38.4%
Operating Margin Operating profit as % of sales
-9.9%
↑ +61.6% 13th
FCF / Share Free cash flow per share
$0.00
↑ +100.6%
Long-Term Debt Long-term obligations
$148.74M
↑ +4.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
11
Financial Health
23
Cash Quality
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 65 quarters